Laura Indolfi

Form D signer

Laura Indolfi

Chief Executive Officer at PanTher Therapeutics

Form D signer

Capital raised by PanTher Therapeutics

$3.0M+$3.0M latest round

1 Form D filing · first filed Mar 2025 · Austin, TX

CURRENT ROLE: Chief Executive Officer
SECTOR: Biotech
COMPANY FILINGS: 1
TEAM ON FILE: 2
FOUNDED: —
30D INTEREST: 1 ↗

Career

1 company on file

PanTher TherapeuticsBiotech · Austin, TXsince Mar 2025

Chief Executive Officer

Signatory on PanTher Therapeutics's Form D filings · $3.0M raised across 1

Company filings

via EDGAR · Form D for PanTher Therapeutics1

DateCompanyFormAmountRole on filing

Mar 14, 2025PanTher TherapeuticsForm D+$3.0MChief Executive Officer

Form DMar 14, 2025 · PanTher Therapeutics+$3.0Mas Chief Executive Officer

Overview

Last filing Mar 14, 2025

Laura Indolfi is on file as Chief Executive Officer at PanTher Therapeutics in Austin, TX. PanTher Therapeutics has 1 Form D filing on record, $3.0M raised in total. Laura Indolfi appears as a signatory on the company's filings.

Teammates

PanTher Therapeutics · 1

D MackeyDirector

Products

PanTher Therapeutics · 1

PTM-101Oncology therapy

PTM-101 is an innovative, absorbable polymer film designed to deliver paclitaxel, a potent chemotherapy agent, directly to the peritumoral region. This targeted delivery method allows for sustained, high-dose administration while avoiding the systemic side effects typically associated with chemotherapy.